Security
VistaGen Therapeutics, Inc. Common Stock · VSTA
VSTAOTCCommon stockHistorical · closed May 10, 2016CIK 1411685Updated Nov 2, 2026
Name history
Excaliber Enterprises, Ltd. · through Jun 8, 2011
Current security for this SEC filerVTGN · NASDAQ
VSTA price & chart
Historical security
This listing closed May 10, 2016. Live provider charts are shown only for current listings.
Current security: VTGN
About the company
Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of rapid-onset neurocircuitry-focused intranasal product candidates called pherines. Vistagen’s pherine product candidates are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options, if successfully developed and approved. Vistagen’s most advanced intranasal pherine product candidates are fasedienol for the acute treatment of social anxiety disorder, itruvone for treatment of major depressive disorder, and refisolone for treatment of vasomotor symptoms (hot flashes) due to menopause. Connect at www. Vistagen.com
In the news
No coverage from other publishers is available.
Recent filings
Costs Associated with Exit or Disposal Activities · Other Events
Items 2.05, 8.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
Show 5 more recent filings
Financials
FY 2026 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 65,056,000Source | 92,307,000Source | 131,068,000Source | 80,929,000Source | 102,496,000Source | 35,736,000Source | 68,924,000Source | 113,548,000Source | 48,564,000Source | 84,341,000Source | 123,653,000Source | 21,089,200Source |
| Property, Plant and Equipment, NetUSD | 480,000Source | 428,000Source | 445,100Source | 516,000Source | 467,000Source | 375,000Source | 530,000Source | 489,000Source | 427,000Source | 476,000Source | 435,000Source | 507,300Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 47,371,000Source | 74,715,000Source | 126,559,200Source | 62,786,000Source | 84,246,000Source | 16,991,000Source | 48,985,000Source | 102,918,000Source | 30,789,000Source | 67,131,000Source | 119,166,000Source | 16,637,600Source |
| Assets, CurrentUSD | 63,245,000Source | 89,941,000Source | 128,114,000Source | 78,934,000Source | 99,948,000Source | 34,310,000Source | 66,716,000Source | 110,838,000Source | 46,943,000Source | 82,076,000Source | 120,672,000Source | 17,507,400Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,475,000Source | 1,381,000Source | 1,480,300Source | 1,759,000Source | 2,370,000Source | 2,580,000Source | 3,536,000Source | 2,474,000Source | 1,540,000Source | 1,594,000Source | 1,432,000Source | 802,700Source |
| Operating Lease, Right-of-Use AssetUSD | 939,000Source | 1,461,000Source | 1,933,600Source | 1,074,000Source | 1,583,000Source | 659,000Source | 1,206,000Source | 1,703,000Source | 801,000Source | 1,335,000Source | 1,820,000Source | 2,260,300Source |
| Other Assets, NoncurrentUSD | 392,000Source | 477,000Source | — | 405,000Source | 498,000Source | 392,000Source | 472,000Source | 518,000Source | 393,000Source | 454,000Source | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 14,136,000Source | 11,185,000Source | 7,783,200Source | 14,590,000Source | 9,522,000Source | 11,255,000Source | 12,159,000Source | 8,745,000Source | 13,044,000Source | 13,951,000Source | 9,367,000Source | 9,009,200Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 40,000Source | 28,000Source | 27,000Source | 39,000Source | 27,000Source | 44,000Source | 29,000Source | 27,000Source | 40,000Source | 29,000Source | 27,000Source | 7,300Source |
| Additional Paid in CapitalUSD | 515,878,000Source | 479,048,000Source | 473,918,200Source | 512,398,000Source | 476,801,000Source | 518,759,000Source | 483,430,000Source | 475,689,000Source | 516,767,000Source | 481,956,000Source | 474,441,000Source | 342,892,500Source |
| Retained Earnings (Accumulated Deficit)USD | -461,043,000Source | -393,997,000Source | -346,692,300Source | -442,144,000Source | -379,908,000Source | -490,347,000Source | -422,727,000Source | -366,947,000Source | -477,317,000Source | -407,632,000Source | -356,214,000Source | -326,851,700Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 13,000Source | 11,000Source | — | 14,000Source | 22,000Source | -7,000Source | 1,000Source | 2,000Source | -2,000Source | 5,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 50,920,000Source | 81,122,000Source | 123,285,000Source | 66,339,000Source | 92,974,000Source | 24,481,000Source | 56,765,000Source | 104,803,000Source | 35,520,000Source | 70,390,000Source | 114,286,000Source | 12,080,000Source |
| Liabilities and EquityUSD | 65,056,000Source | 92,307,000Source | 131,068,000Source | 80,929,000Source | 102,496,000Source | 35,736,000Source | 68,924,000Source | 113,548,000Source | 48,564,000Source | 84,341,000Source | 123,653,000Source | 21,089,200Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 13,529,000Source | 9,621,000Source | 4,164,500Source | 13,644,000Source | 7,523,000Source | 11,192,000Source | 11,155,000Source | 6,236,000Source | 12,795,000Source | 12,612,000Source | 5,123,000Source | 4,567,400Source |
| Operating Lease, Liability, CurrentUSD | 617,000Source | 603,000Source | 533,500Source | 597,000Source | 525,000Source | 720,000Source | 640,000Source | 567,000Source | 699,000Source | 561,000Source | 550,000Source | 485,600Source |
| Accounts Payable, CurrentUSD | 1,280,000Source | 1,039,000Source | 1,737,000Source | 1,831,000Source | 715,000Source | 1,000,000Source | 486,000Source | 1,209,000Source | 1,535,000Source | 653,000Source | 1,547,000Source | 2,473,100Source |
| Operating Lease, Liability, NoncurrentUSD | 431,000Source | 1,110,000Source | 1,713,300Source | 610,000Source | 1,269,000Source | 63,000Source | 783,000Source | 1,423,000Source | 249,000Source | 948,000Source | 1,570,000Source | 2,119,800Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 9,254,000Source | 5,469,000Source | 129,300Source | 8,417,000Source | 3,815,000Source | 9,238,000Source | 6,582,000Source | 2,164,000Source | 8,755,000Source | 8,810,000Source | 2,235,000Source | 787,400Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 61,800,000Source | 88,600,000Source | — | 77,200,000Source | 97,600,000Source | 31,700,000Source | 63,200,000Source | 108,400,000Source | 45,400,000Source | 80,500,000Source | — | — |
| Deferred Revenue, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 714,300Source |
| Deferred Revenue, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 2,314,600Source |
cash flow · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 52,000Source | 40,000Source | 199,000Source | 150,000Source | 127,000Source | 129,500Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 991,000Source | 916,000Source | 3,997,000Source | 4,315,000Source | 2,182,000Source | 3,336,400Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -14,707,000Source | -18,846,000Source | -66,436,000Source | -42,097,000Source | -25,813,000Source | -49,715,100Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | -788,000Source | -877,000Source | -13,148,000Source | -61,000Source | -740,300Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 909,000Source | 1,488,000Source | 30,971,000Source | 3,210,000Source | 128,402,000Source | -1,042,300Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -13,798,000Source | -18,146,000Source | -36,342,000Source | -52,035,000Source | 102,528,000Source | -51,497,700Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 0Source | 6,000Source | 33,000Source | — | — | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 3,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,096,000Source | 1,080,000Source | 1,096,000Source | 1,112,000Source | 991,000Source | 916,000Source | 3,997,000Source | 4,315,000Source | 2,182,000Source | 3,336,400Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 61,800,000Source | 88,600,000Source | 77,200,000Source | 97,600,000Source | 31,700,000Source | 63,200,000Source | 45,400,000Source | 80,500,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | -6,000Source | — |
| General and Administrative ExpenseUSD | — | — | 5,626,000Source | 4,049,000Source | 4,396,000Source | 4,195,000Source | 3,918,000Source | 4,370,000Source | 18,421,000Source | 17,084,000Source | 14,063,000Source | 14,663,600Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 7,000Source | 0Source | 0Source | 7,000Source | 7,000Source | 4,000Source | 5,900Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -18,899,000Source | -14,089,000Source | -19,417,000Source | -12,961,000Source | -13,030,000Source | -15,095,000Source | -69,685,000Source | -51,418,000Source | -29,362,000Source | -59,247,700Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | — | -59,247,700Source |
| Operating ExpensesUSD | — | — | 19,849,000Source | 15,354,000Source | 20,311,000Source | 14,410,000Source | 14,824,000Source | 16,048,000Source | 73,395,000Source | 56,459,000Source | 34,085,000Source | 59,040,700Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 14,200Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | — | — | 167,500Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 303,000Source | 234,000Source | 258,000Source | 183,000Source | 1,476,000Source | 244,000Source | 1,269,000Source | 486,000Source | 1,064,000Source | — |
| Other Nonoperating Income (Expense) | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
| Proceeds from Issuance of Common Stock | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | — | — | — | -227,000Source |
| Operating Income (Loss)USD | — | — | -19,546,000Source | -15,120,000Source | -20,053,000Source | -14,227,000Source | -13,348,000Source | -15,804,000Source | -72,126,000Source | -55,973,000Source | -33,021,000Source | -59,268,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -18,899,000Source | -14,089,000Source | -19,417,000Source | -12,954,000Source | -13,030,000Source | -15,095,000Source | -69,678,000Source | -51,411,000Source | -29,358,000Source | -59,241,800Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 7,000Source | 0Source | 0Source | 7,000Source | 7,000Source | 4,000Source | 5,900Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -18,899,000Source | -14,089,000Source | -19,417,000Source | -12,961,000Source | -13,030,000Source | -15,095,000Source | -69,685,000Source | -51,418,000Source | -29,362,000Source | -59,247,700Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.45Source | -0.46Source | -0.54Source | -0.42Source | -0.3Source | -0.47Source | -1.83Source | -1.67Source | -1.52Source | -8.51Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.45Source | -0.46Source | -0.54Source | -0.42Source | -0.3Source | -0.47Source | -1.83Source | -1.67Source | -1.52Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 42,234,405Source | 30,711,872Source | 35,749,160Source | 30,632,347Source | 42,980,174Source | 31,930,665Source | 38,073,926Source | 30,877,029Source | 19,354,500Source | 6,958,749Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 42,234,405Source | 30,711,872Source | 35,749,160Source | 30,632,347Source | 42,980,174Source | 31,930,665Source | 38,073,926Source | 30,877,029Source | 19,354,500Source | — |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | — | — | — | — | 129,500Source |
| General and Administrative ExpenseUSD | — | — | 5,626,000Source | 4,049,000Source | 4,396,000Source | 4,195,000Source | 3,918,000Source | 4,370,000Source | 18,421,000Source | 17,084,000Source | 14,063,000Source | 14,663,600Source |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | — | 26,200Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 647,000Source | 1,031,000Source | 630,000Source | 1,273,000Source | 319,000Source | 711,000Source | 2,441,000Source | 4,557,000Source | 3,351,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | — | -59,247,700Source |
| Operating ExpensesUSD | — | — | 19,849,000Source | 15,354,000Source | 20,311,000Source | 14,410,000Source | 14,824,000Source | 16,048,000Source | 73,395,000Source | 56,459,000Source | 34,085,000Source | 59,040,700Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 14,200Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Research and Development ExpenseUSD | — | — | 14,223,000Source | 11,305,000Source | 15,915,000Source | 10,215,000Source | 10,906,000Source | 11,678,000Source | 54,974,000Source | 39,375,000Source | 20,022,000Source | 44,377,100Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 303,000Source | 234,000Source | 258,000Source | 183,000Source | 1,476,000Source | 244,000Source | 1,269,000Source | 486,000Source | 1,064,000Source | — |
| Other Nonoperating Income (Expense) | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
Filing attachments
vtgn-20260814xex991.htm · 8-K · 2026-08-14
EX-99.1 2 vtgn-20260814xex991.htm EX-99.1 Document Exhibit 99.1 Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies FDA engagement planned during the current quarter regarding potential future Phase 3 path forward for fasedienol in social anxiety disorder Appointments of Angel S. An…
Read attachment ↗vtgn20260806ex991.htm · 8-K · 2026-08-06
EX-99.1 2 vtgn20260806ex991.htm EX-99.1 Document EXHIBIT 99.1 Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder Repeat dose of fasedienol demonstrated favorable safety and tolerability similar to single dose Efficacy signals were observed across primary and secondary endpoints in repeat dose and single dose Prespecified analysis of patients with very severe social anxiety disorder demonstrated nominally statistically s…
Read attachment ↗vtgn20260731ex991.htm · 8-K · 2026-07-31
EX-99.1 3 vtgn20260731ex991.htm EX-99.1 Document EXHIBIT 99.1 Vistagen Appoints Douglas J. Williamson to its Board of Directors Dr. Williamson brings nearly three decades of leadership experience in neuroscience drug development, clinical research, and regulatory strategy SOUTH SAN FRANCISCO, Calif.--(GLOBE NEWSWIRE) - July 31, 2026, Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercial…
Read attachment ↗vtgn-20260615xex991.htm · 8-K · 2026-06-15
EX-99.1 2 vtgn-20260615xex991.htm EX-99.1 Document Exhibit 99.1 Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder; topline results expected this month Completed randomized portion of fasedienol Phase 2 repeat dose study; topline results expected in third quarter 2026 Achieved minimum ICH E1 safety exposure recommendations across fasedi…
Read attachment ↗vtgn8-k20260512ex991.htm · 8-K · 2026-05-12
EX-99.1 2 vtgn8-k20260512ex991.htm EX-99.1 Document EXHIBIT 99.1 Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Fasedienol nasal spray has been well-tolerated in patients with social anxiety disorder with no new drug-related safety findings after as-needed use in daily life for up to 12 months Clinically relevant improvement in social anxiety over time was ob…
Read attachment ↗pal-4lplvprex991.htm · 8-K · 2026-05-08
EX-99.1 2 pal-4lplvprex991.htm EX-99.1 Document EXHIBIT 99.1 Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder Topline results for the randomized portion of PALISADE-4 are expected in the second quarter of 2026 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE) - May 8, 2026, Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with no…
Read attachment ↗